Previous close | 8.46 |
Open | 8.52 |
Bid | 8.74 x 300 |
Ask | 8.78 x 400 |
Day's range | 8.31 - 8.99 |
52-week range | 7.61 - 27.48 |
Volume | |
Avg. volume | 1,034,881 |
Market cap | 1.187B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.59 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 32.29 |
SAN FRANCISCO, April 30, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.
Key Insights Institutions' substantial holdings in Vir Biotechnology implies that they have significant influence over...
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).